Patient profiles
Patient profiles
Help identify patients in your practice who may benefit from ▼LYFNUA® (gefapixant)
Patients with chronic cough, including refractory or unexplained chronic cough, may experience:
A nonproductive cough1,2
Stress urinary incontinence3,4
Dizziness, headaches, or exhaustion3,4
Multiple meetings with general practitioners and specialists1,6
Speech interruptions3,4
Multiple tests or treatments in an effort to reduce their cough1,6
Anxiousness, depressive feelings, or sleep disruptions3-5
Disruption in social and recreational activities1,4
Here are 2 hypothetical patient profiles that illustrate potential experiences of adults with refractory or unexplained chronic cough (RCC) as well as what a patient’s journey could look like with LYFNUA®.
Meet Gemma
LYFNUA® has helped Gemma cough less and thus feel more comfortable going out
- 63-year-old nonsmoker with a history of chronic cough for 10 years
- Previously diagnosed and adequately treated for mild asthma
- No other potential causes of her cough were identified, despite a thorough evaluation
- Experienced nightly bouts of coughing that kept her from having a restful sleep
- Refractory chronic cough: cough associated with a comorbid condition (e.g. asthma, GERD, or UACS, post-nasal drip) that persisted despite adequate treatment of the comorbid condition
- Patient was prescribed LYFNUA® 45 mg twice daily and instructed to continue with her asthma regimen
Meet Tae-Hyun
LYFNUA® has helped Tae-Hyun focus on more than just chronic cough
- 55-year-old nonsmoker with a persistent dry cough for 2 years
- Cough impacted social life and singing group
- Experienced uncontrollable coughing while singing or talking
- Thorough evaluation did not identify any cough-associated conditions
- Refractory or Unexplained Chronic Cough: persistent cough despite thorough investigation and/or treatment according to published practice guidelines8
- Tae-Hyun was prescribed LYFNUA® 45 mg twice daily
INDICATION
LYFNUA® is indicated in adults for the treatment of refractory or unexplained chronic cough (RCC).7
References:
- Satia I et al. Clin Med (Lond). 2016;16(Suppl 6):S92-S97.
- Gibson P, Wang G, McGarvey L et al., Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. Chest. 2016 Jan;149(1):27-44. doi: 10.1378/chest.15-1496. Epub 2016 Jan 6.
- French CL, Irwin RS, Curley FJ et al.,Impact of chronic cough on quality of life. Arch Intern Med. 1998 Aug 10-24;158(15):1657-61.
- Kuzniar TJ, Morgenthaler TI, Afessa B, Lim KG. Chronic cough from the patient’s perspective. Mayo Clin Proc. 2007 Jan;82(1):56-60.
- Dicpinigaitis PV, Tso R, Banauch G. Prevalence of depressive symptoms among patients with chronic cough. Chest. 2006 Dec;130(6):1839-43.
- Zeiger RS, Schatz M, Hong B et al., Patient-Reported Burden of Chronic Cough in a Managed Care Organization. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1624-1637.e10.
- LYFNUA®, Summary of product characteristics, 09/2023, section 4.1 and 4.8
▼ LYFNUA® (gefapiksant) 45 mg filmdrasjerte tabletter
Terapeutisk indikasjon: Lyfnua er indisert til voksne til behandling av refraktær eller uforklarlig kronisk hoste.
Dosering og administrasjonsmetode: Anbefalt dose av Lyfnua er én 45 mg tablett tatt oralt to ganger daglig med eller uten mat. Pasienter med alvorlig nyresvikt (eGFR < 30 mL/minutt/1,73 m²) som ikke krever dialyse, bør få en redusert dose på én 45 mg tablett som tas én gang daglig.
Pakker og priser (MRP): 56 filmdrasjerte tabletter (blisterpakke), 45 mg: kr 1445,90. Reseptgruppe: C.
Utvalgt sikkerhetsinformasjon:
Spesielle advarsler og forholdsregler for bruk: For pasienter med OSA (obstruktiv søvnapné), bør passende behandling for OSA vurderes før behandling med Lyfnua igangsettes. Lyfnua bør brukes med forsiktighet hos pasienter med kjent overfølsomhet for sulfonamider. Behandling med gefapiksant skal vurderes og tilpasses hos pasienter som utvikler en akutt infeksjon i nedre luftveier.
Fertilitets-, graviditets- og ammeinformasjon: Bruk av Lyfnua bør unngås under graviditet, hos kvinner med reproduksjonsmuligheter som ikke bruker prevensjon, og for ammende kvinner.
Bivirkninger: De vanligste bivirkningene med Lyfnua (som kan påvirke mer enn 1 av 10 personer) inkluderer smakforstyrrelser: dysgeusi (endringer i smakssansen, 41%), ageusi (tap av smakssans, 15%) og hypogeusi (redusert smakssans, 11%).
Konsulter LYFNUA SmPC 09/2023 før forskrivning eller bruk for fullstendig informasjon om dosering, kontraindikasjoner, advarsler og forholdsregler, interaksjoner og bivirkninger.
MSD (Norge) AS, Postboks 1S79 Vika, 0118 Oslo, tlf. 32 20 73 00 faks 32 20 73 10.
Copyright © 2025 Merck & Co., lnc., Rahway, NJ, USA og dets datterselskaper. Alle rettigheter forbeholdt.
NO-NON-00562
